FENC May 2024 10.000 put
| Previous close | 2.7500 |
| Open | 0.7000 |
| Bid | 0.8000 |
| Ask | 5.5000 |
| Strike | 10.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.7000 - 2.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) largest shareholders are individual investors who were rewarded as market cap surged US$25m last week
Key Insights The considerable ownership by individual investors in Fennec Pharmaceuticals indicates that they...
GlobeNewswireFennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement with Norgine to Commercialize PEDMARQSI™ in Europe, Australia, and New Zealand ~ ~ Amended PEDMARK Permanent J-code 07901 Became Effective April 1, 2024 ~ ~ Company Has Approximately $51 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30
- GlobeNewswire
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May
